DOCSLIB.ORG

Cancer Treatment Reviews

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cancer Treatment Reviews CANCER TREATMENT REVIEWS AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.1 • Guide for Authors p.4 ISSN: 0305-7372 DESCRIPTION . Cancer Treatment Reviews is an international journal that provides state of the art, authoritative review articles to the clinician and researcher to keep them abreast of modern concepts and the latest developments in cancer treatment research. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center IMPACT FACTOR . 2020: 12.111 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . Scopus PubMed/Medline Current Contents - Clinical Medicine Science Citation Index Index to Scientific Reviews Research Alert Medical Documentation Service SIIC Data Bases EDITORIAL BOARD . Editors A Cervantes, University of Valencia, Biomedical Research Institute, Inclivia, Department of Hematology and Medical Oncology, Valencia, Spain AUTHOR INFORMATION PACK 25 Sep 2021 www.elsevier.com/locate/ctrv 1 Neurology G. Curigliano, European Institute of Oncology, Milan, Italy breast cancer G. Lenz, University Hospital Munster, Munster, Germany molecular pathogenesis of aggressive lymphoma, NF-κB pathway, PI3K/AKT signalling, tumour microenvironment R.A. Stahel, University of Zurich, Zurich, Switzerland lung and thoracic oncology Editorial Board S Aebi, Luzern, Switzerland breast cancer and gynecological tumors S. Banerjee, London, United Kingdom Gynaecological cancers, ovarian, endometrial, cervical cancers, PARP inhibitors D. Bedognetti, Doha, Qatar Tumor Biology Immunology J. Bellmunt, Barcelona, Spain Solid Tumor Oncology (GU & GI) S Bielack, Stuttgart, Germany pediatric oncology, adolescents and young adults with cancer, bone sarcoma J. Bruix, Barcelona, Spain hepatocellular carcinoma, intrahepatic chilangiocarcinoma, diagnosis and treatment R. Califano, Manchester, United Kingdom small cell lung cancer and non small cell lung cancer , egfr , alk and immunotherapy F. Cardoso, Lisboa, Portugal biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents P. Casali, Milano, Italy adult sarcomas, including gastrointestinal stromal tumours A. Chan, Sydney, Australia Head and neck cancers , Nasopharynx cancer, Epstein Barr Virus R.C. Coleman, Sheffield, United Kingdom Cancer, Bone, Biomarkers, Bisphosphonates, Clinical trials D. De Ruysscher, Maastricht, Netherlands radiation oncology C. Dittrich, Wien, Austria Methodology of clinical trials, Clinical trial regulation, Pancreatic cancer R. Dziadziuszko, Gdansk, Poland T. Eisen, Cambridge, United Kingdom Renal cell carcinoma, Drug development M. Hutchings, Copenhagen, Denmark lymphoma K Jordan, Heidelberg, Germany Internal Medicine and Haematology and Oncology M. Ladetto Hemato-Oncology F. Lordick, Leipzig, Germany hematology and oncology R.J. Mayer, Boston, Massachusetts, United States of America hematology and oncology O Michielin, Lausanne, Switzerland translational oncology C. Pezaro, Melbourne, Australia Genitourinary cancer, Prostate cancer, Clinical research, Translational research. M.R. Posner, New York, New York, United States of America Hematology-Oncology, Cancer (Oncology) A. Prat, Barcelona, Spain breast cancer -omics, and clinical implementation of omic-based assays. Specialties: Breast Cancer Gene Expression Profiling M. Preusser, Wein, Austria characterization of inflammatory infiltrates and immune checkpoint molecules in cancer, anti-cancer drugs including immunotherapies S.A. Quezada, London, United Kingdom AUTHOR INFORMATION PACK 25 Sep 2021 www.elsevier.com/locate/ctrv 2 Immune Regulation and Tumour Immunotherapy C. Sessa, Bern, Switzerland Obstetrics and Gynaecology, Pharmacology J. Tabernero, Barcelona, Spain colorectal cancer K. Tamura Breast and Medical Oncology P Tan, Singapore, Singapore gastric cancer M. Weller, Zurich, Switzerland brain tumors and the diagnosis and therapy of glioblastoma and other primary brain tumors. Y.L. Wu, Guangzhou, China Multidisciplinary therapy and translational medicine on lung cancer, Evidence-based medicine in Oncology AUTHOR INFORMATION PACK 25 Sep 2021 www.elsevier.com/locate/ctrv 3 GUIDE FOR AUTHORS . Aims and scope Cancer Treatment Reviews is an international review journal that will keep both the clinician and researcher abreast of modern concepts and developments in cancer treatment research through the publication of state of the art, authoritative reviews; evidence-based reviews (using a priori defined selection process to identify key articles from the literature and reviewing them in the form of a structured abstract, evidence summary and commentary); and systematic reviews. Please note that the journal will not accept original articles (including meta analyses). Types of contribution Authors will be asked to assign their contribution to one of the following areas: • Comments on Controversy • Tumour Review • Anti-tumour Treatment • New Drugs • Complications of Treatment • General and Supportive Care • Laboratory-Clinic Interface • Systematic or Meta-analysis Studies The journal has a limit of 5000 words (excluding any tables or figures) and 6 figures and/or tables for each review article. A maximum of 100 references is recommended although exceptions can be made subject to the approval of the Editors. Submission checklist You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details. Ensure that the following items are present: One author has been designated as the corresponding author with contact details: • E-mail address • Full postal address All necessary files have been uploaded: Manuscript: • Include keywords • All figures (include relevant captions) • All tables (including titles, description, footnotes) • Ensure all figure and table citations in the text match the files provided • Indicate clearly if color should be used for any figures in print Graphical Abstracts / Highlights files (where applicable) Supplemental files (where applicable) Further considerations • Manuscript has been 'spell checked' and 'grammar checked' • All references mentioned in the Reference List are cited in the text, and vice versa • Permission has been obtained for use of copyrighted material from other sources (including the Internet) • A competing interests statement is provided, even if the authors have no competing interests to declare • Journal policies detailed in this guide have been reviewed • Referee suggestions and contact details provided, based on journal requirements For further information, visit our Support Center. BEFORE YOU BEGIN Ethics in publishing Please see our information on Ethics in publishing. AUTHOR INFORMATION PACK 25 Sep 2021 www.elsevier.com/locate/ctrv 4 Studies in humans and animals If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study. Informed consent and patient details Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and
Load more

Recommended publications
  • Current Problems in Cancer: Case Reports
    CURRENT PROBLEMS IN CANCER: CASE REPORTS AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Abstracting and Indexing p.1 • Editorial Board p.1 • Guide for Authors p.10 ISSN: 2666-6219 DESCRIPTION . Current Problems in Cancer: Case Reports is an international, peer-reviewed open access Journal which aims to fortify the field of oncology by publishing original case reports featuring prevention, diagnosis and treatment of cancer, supportive care, quality of life and rehabilitation. A companion title to Current Problems in Cancer, the Journal provides a global forum for clinicians and researchers to share their personal experiences through case reports, striving to inform clinical cancer research and care. ABSTRACTING AND INDEXING . Directory of Open Access Journals (DOAJ) EDITORIAL BOARD . Editor-in-Chief Nam Quoc Bui, Stanford University School of Medicine, Stanford, California, United States of America Area of Expertise: Sarcoma, Developmental Therapeutics Associate Editors Satya (Nanu) Das, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States of America Areas of Expertise: Gastrointestinal Oncology, Phase I, Drug Development Sunil A. Reddy, Stanford University, Stanford, California, United States of America Cutaneous Oncology , Evidence-Based Medicine, Lymphoma Kay T. Yeung, University of California San Diego Moores Cancer Center, La Jolla, California, United States of America Breast oncology Lisa C. Zaba, Stanford University School of Medicine, Stanford, California, United States of America Supportive Onco-dermatology, melanoma, merkel cell Advisory Reviewer Board Carlos A Alarcón Rojas, Veracruzana University, Xalapa, Mexico Cancer, Epidemiology, Survival, Biostatistics Syed Muhammad Ali, Weill Cornell Medicine - Qatar, Doha, Qatar General and Colorectal Surgery Moustafa Alkhalil, Hamad Medical Corporation, Doha, Qatar head and neck cancer AUTHOR INFORMATION PACK 29 Sep 2021 www.elsevier.com/locate/cpccr 1 Fernando A.
    [Show full text]
  • Myeloid-Derived Suppressor Cells in Gastrointestinal Cancers: a Systemic Review
    Thomas Jefferson University Jefferson Digital Commons Division of Internal Medicine Faculty Papers & Presentations Division of Internal Medicine 1-15-2021 Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review. Maham Farshidpour Monjur Ahmed Shilpa Junna Juanita L. Merchant Follow this and additional works at: https://jdc.jefferson.edu/internalfp Part of the Internal Medicine Commons Let us know how access to this document benefits ouy This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. ISSN 1948-5204 (online) World Journal of Gastrointestinal Oncology World J Gastrointest Oncol 2021 January 15; 13(1): 1-91 Published by Baishideng Publishing Group Inc World Journal of Gastrointestinal W J G O Oncology Contents Monthly Volume 13 Number 1 January 15, 2021 THERAPEUTIC AND DIAGNOSTIC GUIDELINES
    [Show full text]
  • Translational Oncology
    TRANSLATIONAL ONCOLOGY AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.1 • Guide for Authors p.22 ISSN: 1936-5233 DESCRIPTION . Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials. IMPACT FACTOR . 2020: 4.243 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . PubMed/Medline Scopus Directory of Open Access Journals (DOAJ) EDITORIAL BOARD . Co-Editors-in-Chief Bushra Ateeq, Indian Institute of Technology Kanpur, Kanpur, India Genetic/epigenetic alterations in prostate cancer, Cancer Biomarkers and Drug Targets, Mechanism of Drug resistance, non-coding RNAs in cancer. Justin Durla Lathia, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, United States of America Cancer stem cells, Glioblastoma, Cell-Cell Communication, Adhesion, Sex Differences Caroline E. Nunes-Xavier, Radium Hospital Institute for Cancer Research, Oslo, Norway Immune checkpoint proteins, Immunotherapy, Protein tyrosine phosphatase Günter Schneider, University Medical Center Göttingen, , Germany Analysis of signaling, cell cycle regulation, transcriptional regulation, and apoptosis, Molecular biology of GI-cancers Yu Sun, Chinese Academy of Sciences Shanghai Institute of Nutrition and Health, Shanghai, China Cancer Resistance, Tumor Microenvironment, Cellular Senescence, Aging and Age-related diseases, , Verna D.N.K.
    [Show full text]
  • Print Special Issue Flyer
    IMPACT FACTOR 6.639 an Open Access Journal by MDPI Prostate Cancer: Past, Present, and Future Guest Editor: Message from the Guest Editor Prof. Dr. Ajay Pratap Singh This Special Issue of the Cancers (2017 Impact Factor: Cancer Biology Program, Mitchell 5.326) will cover all aspects of prostate cancer, which is the Cancer Institute, University of most common non-cutaneous malignancy among men, South Alabama, Mobile, AL 36604, USA with nearly 1.3 million new cases diagnosed globally in asingh@ 2018. This Special Issue intends to publish emerging data, health.southalabama.edu expert opinions, and reviews to add to the growing knowledge base, and to derive meaningful interpretations from available research and clinical insights in scientific literature. Deadline for manuscript submissions: A broad range of studies on prostate cancer (research, closed (15 November 2019) clinical, outreach, and public health) will be considered for inclusion in this Special Issue. We encourage you to submit original, empirical studies as well as systematic reviews or meta-analyses. Short reports and methodological papers will also be considered. Especially, we encourage the submission of interdisciplinary work and multi-country collaborative research. Keywords Prostate cancer Cancer health disparities Molecular pathogenesis Tumor microenvironment Prevention and control Biomarkers Treatments mdpi.com/si/25111 SpeciaIslsue IMPACT FACTOR 6.639 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Samuel C. Mok Cancers is an international online journal addressing both Department of Gynecologic clinical and basic science issues related to cancer research. Oncology and Reproductive The journal is publishing in Open Access format, which will Medicine, The University of Texas MD Anderson Cancer Center, certainly evolve to ensure that the journal takes full Houston, TX 77030, USA advantage of the rapidly changing world of information and knowledge dissemination.
    [Show full text]
  • Specialissue
    IMPACT FACTOR 6.639 an Open Access Journal by MDPI Prognostic and Predictive Markers in Pancreatic Cancer Guest Editors: Message from the Guest Editors Dr. Eugene J. Koay Dear Colleagues, Department of Radiation Oncology, University of Texas MD Significant progress has been made in the understanding Anderson Cancer Center, of the biological underpinnings of pancreatic cancer in Houston, TX 77030, USA recent years. Coupled with this progress, multiple groups [email protected] have identified biomarkers that may aid in our early Dr. Aatur D. Singhi detection of the disease, personalization of therapy for Department of Pathology, patients, measurement of treatment response, and University of Pittsburgh Medical imaging of the cancer. Such biomarkers have been Center, Pittsburgh, PA 15232, USA identified in a wide array of information sources, including [email protected] but not limited to tissue, blood, urine, imaging, electronic health records, and internet search data. We invite you to share your work related to biomarkers of pancreatic cancer Deadline for manuscript in this special issue of Cancers. submissions: closed (31 August 2021) Dr. Eugene J. Koay Dr. Aatur D. Singhi Guest Editors mdpi.com/si/65604 SpeciaIslsue IMPACT FACTOR 6.639 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Samuel C. Mok Cancers is an international online journal addressing both Department of Gynecologic clinical and basic science issues related to cancer research. Oncology and Reproductive The journal is publishing in Open Access format, which will Medicine, The University of Texas MD Anderson Cancer Center, certainly evolve to ensure that the journal takes full Houston, TX 77030, USA advantage of the rapidly changing world of information and knowledge dissemination.
    [Show full text]
  • Effectiveness of Interventions for Improving Timely Diagnosis of Breast and Cervical Cancers in Low and Middle-­ Income Countries: a Systematic Review Protocol
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2020-042788 on 7 December 2020. Downloaded from Effectiveness of interventions for improving timely diagnosis of breast and cervical cancers in low and middle- income countries: a systematic review protocol Chukwudi Arnest Nnaji ,1,2 Paul Kuodi ,3 Fiona M Walter ,4 Jennifer Moodley 1,5,6 To cite: Nnaji CA, Kuodi P, ABSTRACT Strengths and limitations of this study Walter FM, et al. Effectiveness Introduction Breast and cervical cancers pose a major of interventions for improving public health burden globally, with disproportionately ► This protocol was designed in accordance with stan- timely diagnosis of breast high incidence, morbidity and mortality in low- and and cervical cancers in dard systematic review protocol guidelines. middle- income countries (LMICs). The majority of low and middle-income ► Literature search will be comprehensive, covering women diagnosed with cancer in LMICs present with countries: a systematic both peer-reviewed and relevant grey literature. late- stage disease, the treatment of which is often review protocol. BMJ Open ► No language restriction will be applied in the search. 2020;10:e042788. doi:10.1136/ costlier and less effective. While interventions to ► It is possible that the review will not include all rele- bmjopen-2020-042788 improve the timely diagnosis of these cancers are vant literature available, as some may not be acces- increasingly being implemented in LMICs, there is ► Prepublication history and sible at the time of review. uncertainty about their role and effectiveness. The additional material for this paper ► The overall strength and applicability of the synthe- is available online.
    [Show full text]
  • Get App Journal Flyer
    IMPACT FACTOR 6.639 an Open Access Journal by MDPI The Irish Association for Cancer Research (IACR), Signal Transduction Society (STS) and Spanish Association for Cancer Research (ASEICA) are affiliated with Cancers. IMPACT FACTOR 6.639 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Samuel C. Mok Cancers is an international, online journal addressing both clinical and basic science issues related to cancer Associate Editors Prof. Dr. David Wong research. The journal will continue its open access Dr. Deepak Nagrath format, which will certainly evolve to ensure that the Prof. Dr. Mary Frances McMullin journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment. Author Benefits Open Access Unlimited and free access for readers No Copyright Constraints Retain copyright of your work and free use of your article Thorough Peer-Review Rapid Processing and Immediate Publication upon Acceptance Coverage by Leading Indexing Services SCIE-Science Citation Index Expanded (Clarivate Analytics), PubMed (NLM), Scopus (Elsevier) No Space Constraints, No Extra Space or Color Charges No restriction on the length of the papers, number of figures or colors Discounts on Article Processing Charges (APC) If you belong to an institute that participates with the MDPI Institutional Open Access Program (IOAP) Aims and Scope Cancers features (1) Original Articles reporting on novel and original findings; (2) Clinical Observations accompanied by analysis and discussion; (3) Communications reporting small scale studies that include important new information; (4) timely Reviews and Topical Issues on cutting edge fields in oncology.
    [Show full text]
  • Specialissue
    IMPACT FACTOR 6.639 an Open Access Journal by MDPI Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer Guest Editor: Message from the Guest Editor Prof. Ranjit Manchanda Dear Colleagues, Wolfson Institute of Preventive Medicine, CRUK Barts Cancer There have been a number of strides in our understanding Centre, Queen Mary University of of factors that affect cancer risk, risk assessment, London, Centre for Cancer Prevention, Charterhouse ascertainment of women at increased risk, risk Square, London EC1M 6BQ, UK stratification, as well as management strategies, including [email protected] screening and prevention, in recent years. We welcome submissions in gynaecological or women’s cancers that cover any relevant topic in the areas of cancer Deadline for manuscript risk, risk assessment (including ascertainment), and risk submissions: management. closed (31 January 2021) Prof. Ranjit Manchanda Guest Editor mdpi.com/si/36749 SpeciaIslsue IMPACT FACTOR 6.639 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Samuel C. Mok Cancers is an international online journal addressing both Department of Gynecologic clinical and basic science issues related to cancer research. Oncology and Reproductive The journal is publishing in Open Access format, which will Medicine, The University of Texas MD Anderson Cancer Center, certainly evolve to ensure that the journal takes full Houston, TX 77030, USA advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.
    [Show full text]
  • Visualization and Bibliometric Analysis of Camp Signaling System Research
    Journal of Cancer 2021, Vol. 12 358 Ivyspring International Publisher Journal of Cancer 2021; 12(2): 358-370. doi: 10.7150/jca.47158 Research Paper Visualization and bibliometric analysis of cAMP signaling system research trends and hotspots in cancer Caoli Tang1, Duanya Liu1, Yongsheng Fan1, Jun Yu1, Cong Li1, Jianmei Su1,2 and Chunhong Wang1 1. Department of Preventive Medicine, School of Public Health, Wuhan University, Donghu Road 115, Wuhan 430071, Hubei, China. 2. Key Laboratory of Regional Development and Environmental Response, Faculty of Resources and Environmental Science, Hubei University, Friendship Avenue 368, Wuhan 430062, Hubei, China. Corresponding author: Department of Preventive Medicine, School of Public Health, Wuhan University, Donghu Road 115, Wuhan 430071, Hubei, China. E-mail address: [email protected] (J. Su); [email protected] (C. Wang). © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.04.18; Accepted: 2020.10.02; Published: 2021.01.01 Abstract Cyclic adenosine monophosphate (cAMP) is an essential second messenger that widely distributed among prokaryotic and eukaryotic organisms. cAMP can regulate various biological processes, including cell proliferation, differentiation, apoptosis and immune functions. Any dysregulation or alteration of cAMP signaling may cause cell metabolic disorder, immune dysfunction and lead to disease or cancer. This study aimed to conduct a scientometric analysis of cAMP signaling system in cancer field, and explored the research trend, hotspots and frontiers from the past decade. Relevant literatures published from 2009 to 2019 were collected in the Web of Science Core Collection database.
    [Show full text]
  • Current Status and Trend of the Publication to the SCI and SCIE Journals in the Fi Eld of Radiation Oncology in Korea for 30 Years
    Original Article Radiat Oncol J 2012;30(1):14-19 http://dx.doi.org/10.3857/roj.2012.30.1.14 pISSN 2234-1900 · eISSN 2234-3156 Current status and trend of the publication to the SCI and SCIE journals in the fi eld of radiation oncology in Korea for 30 years Won Park, MD, Seung Jae Huh, MD Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Purpose: We collected the data of Science Citation Index (SCI) and SCI Expended (SCIE) papers written by the members of the Korean Society of Radiation Oncology (KOSRO) to analyze the current status and the future trend. Materials and Methods: We searched the database of SCIE for the period from 1981 to 2011 at the Web of Knowledge site. Articles, reviews or proceedings written by KOSRO members as the fi rst or corresponding authors were included. Search terms were the following combination of subject headings: therapeut radiol, radiat oncol, Korea. For National Cancer Center, combined search terms such as natl canc ctr, Korea and the names of faculties were applied. Results: The total number of SCIE papers was 547. Numbers of the published papers in 1995, 2000, 2005, and 2010, were increased continuously, which was 2, 14, 40, and 83, respectively. The average impact factor was 2.9. The papers were published at the 134 different journals. The proportion of “International Journal of Radiation Oncology Biology Physics” was 23.4% of all the papers. The number and proportions of papers by subject categories were 87 (15.9%) in biology, 73 (13.3%) in physics and 387 (70.6%) in clinics.
    [Show full text]
  • Annual Report 2019 Content
    Annual Report 2019 Content Content 2 About MDPI 4 Message from the CEO 6 Key Figures 8 Financial Data 2019 12 Journal Development in 2019 16 Journals Launched in 2019 18 Quality of Service 20 Societies and Partnerships 22 Sciforum Conferences 2019 24 MDPI Conferences in 2020 26 MDPI Books 28 SciProfiles 30 MDPI Other Services 32 Stay Connected 1 MDPI Annual Report 2019 About MDPI About MDPI ▶ www.mdpi.com/about Being a pioneer in academic Open Access publishing, MDPI Flexibility has been focused on serving and strengthening the scientific community since 1996. In 2019, MDPI journals continued to make In a changing and evolving publishing environment, we are constantly impact in a growing Open Access publications market. Our purpose adapting and developing new tools and services. By listening to feedback is to provide a valuable service to the academic community. Our from authors, editors, and readers, we can make changes to better meet mission is to foster scientific exchange in its various forms, across the needs of our research community and keep MDPI relevant. all scientific disciplines. The driving principles behind everything that we do are the following: Simplicity Accessibility All of our tools and services can be found in one place and prioritize user-friendliness. Simple processes keep our editorial process highly We offer access to science and the latest research to readers free- efficient. of-charge. All of our content is published in Open Access format and distributed under a Creative Commons License, which means free distribution and the right to share and re-use published articles.
    [Show full text]
  • The Journal of Cancer Research
    A HISTORY OF THE JOURNAL CANCER RESEARCH Commemorating the Journal’s 75th Anniversary February 15, 2016 Volume 76 Number 4 Cancer Research 75TH ANNIVERSARY Driving Innovation to Prevent and Cure Cancer 615 Chestnut Street, 17th Floor Philadelphia, PA 19106 215-440-9300 \\ AACRJournals.org www.AACRJournals.org The following history of the journal Cancer Research and its predecessors was written by June Eberharter, production editor for the Archives staff in the AACR Executive Office. June Eberharter died two months before this history was published. She had been managing editor for two AACR journals, Clinical Cancer Research and Molecular Cancer Research, and previously worked at most of the major publishing houses in the Philadelphia area — a mentor and teacher to a generation of editors. In her 13 years at the AACR, she applied her considerable editorial skills toward conquering the disease that ultimately took her life. This publication is dedicated to June. Kathleen Case, AACR Archivist 5 | AACR: THE FOUNDING 6 | THE JOURNAL OF CANCER RESEARCH 7 | THE AMERICAN JOURNAL OF CANCER 8 | CANCER RESEARCH, THE NEW JOURNAL • The Post-World War II Years 9 | THE JOURNAL RESTRUCTURED: 1950-1959 10 | THE JOURNAL MATURES: 1960-1969 • Smoking and Cancer 11 | AACR LEADER PROFILE: HUGH J. CREECH, PHD 12 | DOCUMENTING THE WAR ON CANCER: 1970-1979 13 | A DECADE OF INNOVATION: 1980-1989 14 | AACR LEADER PROFILE: MARGARET FOTI, PHD, MD (HC) 14 | ANTICIPATING THE NEW MILLENIUM: 1990-1999 16 | A NEW CENTURY OF DISCOVERY: 2000-2009 17 | CURRENT INITIATIVES: 2010 AND BEYOND 18 | APPENDIX 1. JOURNAL STATISTICS AND RANKINGS • Journal Citation Reports • The Eigenfactor® • The H-Index and SCImago Journal Rank (SJR) TABLE OF CONTENTS 20 | REFERENCES 4 History of Cancer Research AACR: THE FOUNDING Gaslights illuminated the streets of Washington on the evening of May 7, 1907, when a group of seven scientists with a mission met at the new Willard Hotel.
    [Show full text]